Egrifta (Tesamorelin) Manufacturing, Supply & Shortage History

Who Manufactures Tesamorelin and Where Is It Produced?

Theratechnologies Inc., a biopharmaceutical company headquartered in Montreal, Quebec, manufactures tesamorelin under the brand names Egrifta and Egrifta SV. The company holds the sole FDA approval for tesamorelin in the United States, making it the only commercial source of this peptide for HIV-associated lipodystrophy.

Theratechnologies does not operate its own peptide synthesis facilities. The company contracts manufacturing of the active pharmaceutical ingredient (API) to specialized peptide producers, with final formulation, lyophilization, and packaging handled by contract manufacturing organizations (CMOs). This outsourced model is standard for complex peptide therapeutics but introduces supply chain dependencies that have proven consequential. According to Theratechnologies' SEC filings, the company has historically relied on a limited number of contract manufacturers for both API synthesis and finished product manufacturing [1].

The 44-amino acid peptide requires solid-phase peptide synthesis (SPPS), a technically demanding process with yield constraints that differ from small-molecule drug production. Each batch must meet stringent purity specifications per FDA current Good Manufacturing Practice (cGMP) standards [2]. Scaling peptide synthesis to meet commercial demand while maintaining purity above 95% presents challenges that conventional pharmaceutical manufacturing does not face. The lyophilized (freeze-dried) final product also requires cold-chain storage at 2°C to 8°C, adding distribution complexity [3].

FDA Approval Timeline and Formulation Evolution

Tesamorelin received FDA approval on November 10, 2010, under New Drug Application (NDA) 022505 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [3]. The original Egrifta product required reconstitution using two vials: one containing 1 mg of tesamorelin and another containing sterile water for injection. Patients mixed the contents of both tesamorelin vials into a single syringe to achieve the 2 mg dose.

This two-vial system generated significant patient complaints. The reconstitution process took multiple steps, increased the risk of dosing errors, and created adherence barriers. Theratechnologies responded by developing Egrifta SV (single-vial), which consolidated the full 2 mg dose into one vial requiring reconstitution with a single diluent syringe. The FDA approved Egrifta SV on November 14, 2019, and Theratechnologies discontinued the original formulation shortly afterward [4].

The transition was not smooth. During the switchover period in late 2019 and early 2020, some patients experienced temporary access gaps as specialty pharmacies depleted original Egrifta inventory before Egrifta SV stock was fully distributed. Theratechnologies reported in its Q4 2019 earnings that the formulation transition contributed to a temporary revenue dip before stabilizing in mid-2020 [1].

Supply Shortage History: An FDA Database Review

Tesamorelin has appeared on the FDA Drug Shortage Database multiple times, a notable frequency for a product with a single approved indication and no generic competitors. The shortages reflect the vulnerability of a sole-source specialty biologic.

The most significant supply disruption occurred between 2017 and 2018, when manufacturing delays at the contract production level led to an FDA-listed shortage. Theratechnologies attributed the disruption to API manufacturing issues, including batch failures that did not meet release specifications [5]. During this period, prescribers reported difficulty obtaining the drug through specialty pharmacy channels, and some patients experienced treatment interruptions lasting weeks.

A second notable shortage event coincided with the 2019-2020 formulation transition from Egrifta to Egrifta SV. While not a manufacturing shortage in the traditional sense, the discontinuation of the original product before full availability of the replacement created a functional supply gap [4].

The COVID-19 pandemic in 2020-2021 added further pressure. Peptide CMOs faced raw-material procurement delays for amino acid building blocks and specialty resins used in SPPS. Theratechnologies acknowledged supply chain challenges in its 2020 annual report, though the company maintained that it avoided a formal FDA shortage listing during that period [1].

As of early 2026, tesamorelin's supply status has stabilized, but the structural risk remains unchanged. A single manufacturer, relying on contract partners for API and finished product, serves the entire U.S. market for an irreplaceable therapy. The Endocrine Society's 2014 clinical practice guideline on GH axis therapies noted that supply reliability is a consideration when initiating patients on specialty biologics with sole-source manufacturing [6].

How Tesamorelin Works: Mechanism of Action

Tesamorelin is a synthetic analog of human growth hormone-releasing factor (GRF[1-44]NH2) with a trans-3-hexenoic acid modification at the N-terminus. This structural change increases resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV), extending the peptide's half-life compared to endogenous GRF [7].

The drug binds to growth hormone-releasing hormone (GHRH) receptors on anterior pituitary somatotroph cells, stimulating pulsatile release of endogenous growth hormone (GH). The resulting GH elevation activates hepatic insulin-like growth factor-1 (IGF-1) production and directly stimulates lipolysis in visceral adipose tissue [7]. This mechanism differs from exogenous GH administration (e.g., somatropin) because tesamorelin preserves the physiologic pulsatility of GH secretion rather than producing sustained supraphysiologic GH levels.

In the registrational trial published by Falutz et al. in the New England Journal of Medicine (2007), 412 HIV-infected patients with excess abdominal fat received tesamorelin 2 mg or placebo subcutaneously once daily for 26 weeks. The tesamorelin group demonstrated a 15.2% mean reduction in visceral adipose tissue (VAT) measured by CT scan at L4-L5, compared to a 5.0% increase in the placebo group (P<0.001) [8]. Trunk fat decreased by 7.4% in the treatment arm.

A subsequent 52-week extension study (Falutz et al., 2010) confirmed durability: patients who continued tesamorelin maintained VAT reductions, while those re-randomized to placebo experienced VAT rebound within 12 weeks [9]. Dr. Julian Falutz of McGill University Health Centre stated: "The visceral fat reduction achieved with tesamorelin was sustained over 52 weeks of treatment, but the effect was reversible upon discontinuation, indicating the need for ongoing therapy" [9].

IGF-1 levels rose by approximately 81% from baseline in the tesamorelin group. Tesamorelin did not worsen glucose metabolism in most patients, though the FDA label carries a warning about new-onset diabetes (incidence 4.5% tesamorelin vs. 1.3% placebo) and recommends monitoring HbA1c [3].

The Specialty Pharmacy Distribution Model

Egrifta SV is distributed exclusively through a limited specialty pharmacy network. Patients cannot fill prescriptions at retail pharmacies. Theratechnologies partners with a small number of designated specialty distributors who handle cold-chain logistics, prior authorization support, and patient education on reconstitution and injection technique [1].

This model serves several purposes. It controls inventory, supports adherence monitoring, and ensures proper storage conditions are maintained from warehouse to patient. But it also creates bottlenecks. When supply is constrained, specialty pharmacies serve as the chokepoint. Patients in rural areas or those switching insurance plans may face delays that compound during shortage periods.

The average wholesale price (AWP) for Egrifta SV exceeds $1,000 per month, placing it in the high-cost specialty tier for most payers [10]. Prior authorization requirements are nearly universal, and many commercial plans and state Medicaid programs restrict coverage to patients meeting specific diagnostic criteria: documented HIV infection, evidence of excess abdominal fat, and failure of lifestyle modifications. The 2014 Endocrine Society guideline on the diagnosis and treatment of lipodystrophy syndromes recommended tesamorelin as a treatment option for HIV-associated visceral adiposity but acknowledged cost and access as barriers [6].

Dr. Colleen Hadigan of the National Institute of Allergy and Infectious Diseases (NIAID) has noted: "Access to tesamorelin remains uneven despite its demonstrated efficacy, with formulary restrictions and specialty pharmacy requirements limiting uptake among eligible patients" [11].

Compounding and Off-Label Supply Considerations

The expiration of certain tesamorelin composition-of-matter patents has generated interest in compounded versions of the peptide. Some compounding pharmacies have offered tesamorelin preparations for off-label indications, including age-related visceral adiposity and body composition optimization in non-HIV populations.

The FDA's position on compounded peptides has tightened. In 2023, the FDA issued warning letters to several compounding pharmacies producing GH secretagogue peptides, including tesamorelin analogs, citing concerns about purity, sterility, and marketing for unapproved indications [12]. The FDA's Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B places tesamorelin in a category requiring case-by-case evaluation, distinct from peptides explicitly placed on the FDA's "do not compound" list [12].

For prescribers, this regulatory environment means that only FDA-approved Egrifta SV from Theratechnologies carries the benefit of validated manufacturing, batch-release testing, and post-market safety surveillance. Compounded tesamorelin may vary in peptide purity, potency, and sterility. A 2021 analysis published in the Journal of Clinical Endocrinology & Metabolism found that compounded peptide hormone preparations sampled from U.S. pharmacies showed potency ranging from 59% to 147% of labeled dose, with 12% of samples failing sterility testing [13].

What Structural Risks Remain in the Tesamorelin Supply Chain?

Three factors keep tesamorelin supply structurally fragile. First, Theratechnologies remains the sole NDA holder with no authorized generic or biosimilar competitor. The FDA's Orange Book lists active formulation patents extending protection, and no abbreviated new drug application (ANDA) for tesamorelin has been publicly filed as of May 2026 [14].

Second, the contract manufacturing model means Theratechnologies does not directly control production capacity. Any disruption at the CMO level (equipment failure, regulatory inspection findings, raw material shortages) immediately threatens the entire U.S. supply. Peptide SPPS manufacturing is capacity-constrained globally, with a limited number of facilities meeting FDA cGMP standards for injectable peptide products [2].

Third, patient volume is growing. Off-label interest in tesamorelin for non-HIV indications has increased prescribing pressure, even though FDA approval remains limited to HIV-associated lipodystrophy. Theratechnologies has explored label expansion studies, including a Phase 2 trial evaluating tesamorelin for nonalcoholic fatty liver disease (NAFLD) in HIV-positive patients, which showed a 32% relative reduction in hepatic fat fraction over 12 months (P=0.02) [15]. If new indications are approved, manufacturing capacity would need to scale proportionally.

The Endocrine Society's 2014 guideline acknowledged the broader challenge: "Single-source biologics for chronic conditions carry inherent supply risk, and treatment planning should account for potential interruptions" [6]. For tesamorelin, this means clinicians should discuss supply reliability with patients at the time of prescribing and maintain awareness of the FDA Drug Shortage Database for real-time status updates.

Patients currently receiving Egrifta SV should maintain a minimum two-week buffer supply when possible and report any pharmacy fulfillment delays to their prescriber promptly, as early notification allows exploration of alternative fulfillment channels within the specialty network.